Dr. Martin Fan
Recent Articles
US Biopharma In-Licenses 3 New Assets 10/24/2025
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report.
Due to permission requirements, not all quotes are shown.
